|
|
| Biotechnologies Et Génétique > Etude de marché sectorielle |
|
|
|
|
€ 1 200,00 |
Editeur
: |
ZZZ - Biovista |
Langue
: |
Anglais |
Date de publication : |
Juillet 2001 |
Taille du document : |
N/A |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
|
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
Pharmacogenomics 160 pages | Décembre 2000 |
The Human Genome Project and numerous corporate and academic human gene sequencing efforts have revealed, among others, that genes exist in the population in numerous mutated forms, some of which |
1 400,00 €
|
| |
| |
The Genomics Outlook To 2005: Transforming pharmaceutical and diagnostic markets 150 pages | Janvier 2002 |
Genomics is quietly transforming the pharmaceutical industry. Companies are moving from medicinal chemistry based drug discovery and development, to using information provided by genomics. V |
953,48 €
|
| |
| |
05-001: Improving Sales Rep Performance: A Global Analysis 219 pages | Janvier 2005 |
This report is designed to offer insights on how sales executives can align their sales force organization, recruitment and training in a way that reflects the needs and expectations of scientific cus |
1 520,00 €
|
| |
| |
Bioinformatics 150 pages | Décembre 2000 |
Automation has assaulted several levels of biological research generating vast amounts of data. Great leaps in DNA sequencing technology and automation led to a dramatic increase in sequence th |
1 400,00 €
|
| |
| |
03-054: Immunohistochemistry Market Benchmarking Survey 90 pages | Octobre 2003 |
This report provides an overview of the most commonly used methods and products for tissue/sample preparation and antigen detection to help suppliers understand researchers’ experiences, preferences a |
680,00 €
|
| |
| |
Combinatorics 150 pages | Décembre 2000 |
Identified by The Economist (*) as the industry to watch for 1997 in the chemicals sector, Combinatorics (also known as combinatorial chemistry) is an emerging platform technology that uses test t |
1 400,00 €
|
| |
| |
DNA Sequencing and PCR Markets 252 pages | Novembre 2004 |
The focus of this report is to describe the specific segment of the life sciences market called DNA sequencing. This analysis includes all of the generally accepted DNA-oriented analytical activiti |
2 800,00 €
|
| |
| |
03-019: The Market for Microbial Genotyping Products: Research and Testing Applications 183 pages | Juin 2003 |
The report identifies the kits, reagents and instrumentation that are most commonly used for microbial identification and analysis in both the research and testing arenas |
800,00 €
|
| |
| |
Biogenerics: Challenges and Promise 154 pages | Janvier 2005 |
Biogenerics: Challenges and Promise takes an insightful look at the burgeoning biogenerics industry and helps to clarify the complicated regulations that currently govern biogeneric development in bot |
799,20 €
|
| |
| |
Carbohydrate Therapeutics IRCD pages | Juillet 2001 |
Carbohydrates are the only class of biological molecule (there are four main classes: nucleic acids, proteins, lipids, and carbohydrates - commonly known as sugars), that can be found in direct associ |
1 200,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
|
|
The notion of a cheap and reliable computer chip look-alike that performs thousands   of biological reactions is a very attractive one, because it miniaturizes, automates   and accelerates otherwise cumbersome laboratory tasks, at a significantly lower   cost per assay than traditional methods. Applications include the analysis of   genetic material for defects or sequence variations for diagnostic, therapeutic   and forensic purposes, analysis of biological fluids for diagnostic and therapeutic   purposes, and analysis of inter-molecular interactions for drug lead screening   purposes. Developments in assay chemistries, in so-called microfluidics, which   is the handling of minute volumes of liquids, and in ultra-sensitive detection   methodologies, as well as advances in chip manufacturing approaches for bio-assay   purposes, have contributed towards the development of the field. Corporate interest   centers around the potential of biochips to be used as point-of-care diagnostics,   and as high throughput screening platforms for drug lead identification, but a   key challenge is to develop a standardized chip platform that is universally applicable,   much like the computer chip equivalents.
|
|
I) KNOWLEDGE BLOCK 1: TECHNOLOGY SUMMARY
II) KNOWLEDGE BLOCK 2: BUSINESS DEVELOPMENT
III) KNOWLEDGE BLOCK 3: COMPANY DATABASE
IV) KNOWLEDGE BLOCK 4: PATENTS DATABASE
|
|
|
PPLSEN
|
|
|
|
|